GenSight Biologics S.A.
GSGTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,500 | $1,267 | $2,582 | $5,276 |
| % Growth | 18.4% | -50.9% | -51.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1,500 | $1,267 | $2,582 | $5,276 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $12,368 | $19,360 | $18,938 | $22,554 |
| G&A Expenses | $3,583 | $6,499 | $8,006 | $5,680 |
| SG&A Expenses | $3,611 | $7,267 | $8,237 | $5,894 |
| Sales & Mktg Exp. | $28 | $768 | $231 | $214 |
| Other Operating Expenses | $1,334 | $4,336 | $3,242 | $4,953 |
| Operating Expenses | $17,313 | $30,963 | $30,417 | $33,401 |
| Operating Income | -$15,813 | -$29,696 | -$27,835 | -$28,126 |
| % Margin | -1,054.2% | -2,343.8% | -1,078% | -533.1% |
| Other Income/Exp. Net | $1,832 | $3,475 | $215 | -$489 |
| Pre-Tax Income | -$13,981 | -$27,917 | -$27,619 | -$28,615 |
| Tax Expense | $21 | -$1,696 | $5 | $2 |
| Net Income | -$14,001 | -$26,220 | -$27,624 | -$28,617 |
| % Margin | -933.4% | -2,069.5% | -1,069.9% | -542.4% |
| EPS | -0.17 | -0.54 | -0.6 | -0.63 |
| % Growth | 68.5% | 10% | 4.8% | – |
| EPS Diluted | -0.17 | -0.54 | -0.6 | -0.63 |
| Weighted Avg Shares Out | 82,751 | 48,316 | 46,330 | 45,151 |
| Weighted Avg Shares Out Dil | 82,749 | 48,316 | 46,330 | 45,151 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $2,650 | $0 |
| Interest Expense | $1,553 | $3,153 | $2,650 | $2,166 |
| Depreciation & Amortization | $1,059 | $2,179 | $1,061 | $928 |
| EBITDA | -$11,369 | -$20,890 | -$26,774 | -$27,199 |
| % Margin | -757.9% | -1,648.8% | -1,036.9% | -515.5% |